{"id":169,"date":"2025-10-17T11:02:53","date_gmt":"2025-10-17T11:02:53","guid":{"rendered":"https:\/\/openbind.uk\/home\/"},"modified":"2026-05-01T16:12:41","modified_gmt":"2026-05-01T16:12:41","slug":"home","status":"publish","type":"page","link":"https:\/\/openbind.uk\/","title":{"rendered":"Home"},"content":{"rendered":"

OpenBind is a pioneering initiative creating the world\u2019s largest open-access dataset of drug\u2013protein interactions \u2013 to accelerate the development of new treatments.<\/p>

By combining cutting-edge science with open collaboration, OpenBind powers the next generation of machine learning tools for structure-based drug design, freely available to all.<\/p>

The Concept<\/a>Our team of Researchers<\/a>Documents and Tools<\/a><\/div><\/div><\/div><\/section>

Why it matters<\/h2>

Significantly increasing the number of public protein-ligand structures<\/h3>

Using automated chemistry and high throughput X-ray crystallography to significantly increase the number of publicly available protein-ligand structures over a period of 5 years.<\/p><\/div>

Led by Global Experts\u2028<\/h3>

Bringing together a collaboration of pioneers in structural biology and AI including Diamond Light Source, the Universities of Oxford, Washington and Columbia plus the EBI and OMSF.<\/p>Meet the team<\/a><\/div>

Breakthroughs in disease treatment\u00a0<\/h3>

Delivering a core dataset, including predicting molecular structures, designing new molecules and improving research workflows.<\/p><\/div>

AI-ready data\u00a0to reduce drug development time and cost\u2028<\/h3>

Combined with other new methods to reduce trial-and-error experimentation, guide better decision-making, and support more efficient exploration of chemical possibilities.<\/p><\/div><\/div><\/div><\/section>

Announcements<\/h2>